Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 40334148.
- Also identified by DOI 10.1093/bjd/ljaf166 and PMC identifier 12360034.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nemolizumab is a new biologic approved to treat atopic dermatitis. In this perspective piece, we use results from our living systematic review and network meta-analysis to provide perspective on the relative efficacy of nemolizumab compared with other approved targeted systemic treatments.